Insmed Inc. (INSM) Receives $20.75 Average PT from Analysts
Insmed Inc. (NASDAQ:INSM) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the company. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.75.
Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a report on Friday, November 4th. Zacks Investment Research raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. Finally, Piper Jaffray Cos. set a $24.00 price target on shares of Insmed and gave the company a “buy” rating in a report on Sunday, August 21st.
In other news, CFO Andrew T. Drechsler sold 45,000 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $14.67, for a total transaction of $660,150.00. Following the sale, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at approximately $293,400. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Orlov S. Nicole Schaeffer sold 68,774 shares of the stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $11.95, for a total transaction of $821,849.30. Following the sale, the senior vice president now directly owns 37,500 shares in the company, valued at $448,125. The disclosure for this sale can be found here. Insiders own 4.03% of the company’s stock.
Large investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in Insmed by 1.8% in the first quarter. BlackRock Fund Advisors now owns 2,291,187 shares of the biopharmaceutical company’s stock valued at $29,029,000 after buying an additional 41,193 shares during the last quarter. Jennison Associates LLC raised its stake in Insmed by 1.5% in the second quarter. Jennison Associates LLC now owns 1,195,455 shares of the biopharmaceutical company’s stock valued at $11,787,000 after buying an additional 17,951 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Insmed by 32.3% in the second quarter. Ameriprise Financial Inc. now owns 303,803 shares of the biopharmaceutical company’s stock valued at $2,998,000 after buying an additional 74,224 shares during the last quarter. Alps Advisors Inc. purchased a new stake in Insmed during the second quarter valued at about $857,000. Finally, RidgeWorth Capital Management LLC raised its stake in Insmed by 52.2% in the second quarter. RidgeWorth Capital Management LLC now owns 29,843 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 10,241 shares during the last quarter. 91.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Insmed (NASDAQ:INSM) opened at 15.22 on Tuesday. The company’s market capitalization is $941.77 million. The firm’s 50-day moving average price is $13.80 and its 200 day moving average price is $12.47. Insmed has a 52 week low of $9.02 and a 52 week high of $19.30.
Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.02. Equities analysts predict that Insmed will post ($2.57) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Insmed Inc. (INSM) Receives $20.75 Average PT from Analysts” was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of United States & international copyright & trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/27/insmed-inc-insm-receives-20-75-average-pt-from-analysts.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.
Receive News & Stock Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related stocks with our FREE daily email newsletter.